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Prostate cancer is the most common cancer in the United States,
where about 180 000 men were expected to be diagnosed with
prostate cancer in 1999. Approximately 40 000 men die of this
disease every year in the US, according to American Cancer
Society estimation (Landis et al, 1999). Though localized prostate
cancer can be treated with radical surgery or radiation therapy,
there is no curative treatment for advanced disease. In addition,
one third of radically treated patients ultimately experience a
relapse. Endocrine therapy offers only temporary relief, and
chemotherapy is largely ineffective. Prostate cancer shortens life
expectancy of men by approximately 4–5 years compared to the
age-matched general population, and approximately one man out
of 6 has a lifetime risk of developing prostate cancer. This makes a
better understanding of prostate cancer’s nature and the develop-
ment of new treatment methods crucial.
The immunologic status of prostate cancer patients has been
evaluated during the last several years. Immunosuppression is
noted in relatively confined prostate tumours, and a number of
studies demonstrated a significant inhibition of the immune
system at advanced stages in prostate cancer patients (Herr, 1980;
Ivshina et al, 1995; Healy et al, 1998; Salgaller et al, 1998).
However, the exact nature and the level of immunodeficiency in
these patients as well as its clinical, biological and prognostic
significance are still controversial.
During the last decade a great deal of attention has been paid to
the role of dendritic cells (DC) in the development of immune
responses. First described in 1973 (Steinman and Cohn, 1973), DC
originate from CD34+ progenitor cells in the bone marrow. Within
non-lymphoid tissue these cells apparently present as immature
DC with the capacity to recognize, take up, and process antigen.
After acquiring antigen, they can migrate to the lymph nodes and
present the antigen to the T cells, stimulating their differentiation
and clonal expansion. Thus, as antigen presenting cells (APC), DC
play a crucial role in the development of specific antitumour
immune responses (Shurin, 1996). In contrast, suppression of the
DC system may effectively eliminate the induction and develop-
ment of a specific immune reaction. Indeed, it has been recently
shown that DC may undergo apoptosis in vivo and in vitro after
contact with tumour (Esche et al, 1999; Shurin et al, 1999).
Decreased number of DC has been demonstrated during the
progression of melanoma (Toriyama et al, 1993; Stene et al, 1988),
and increased DC infiltration into primary tumour lesions has been
associated with better survival (Becker, 1992; Lotze, 1997).
Prostate cancer has also been studied for the presence of DC
infiltrate. It was shown that the number of DC decreased in the
human prostatic cancer tissue, in comparison to normal prostatic
and benign prostate hyperplasia (BPH) tissues (Davidson et al,
1997; Troy et al, 1998). In addition, reversed correlation between
degree of differentiation and the number of DC within the
prostate was found: the higher the anaplastic rate, the fewer DC
were found in the prostate cancer tissue. One of the explanations
of this finding is that prostate cancer microenvironment effec-
tively suppresses or eliminates DC in situ, thus diminishing the
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(Shurin, 1999).
When it was generally accepted that DC play a major role in the
induction and development of specific immunologic responses,
several clinical trials were initiated which used DC-based
immunotherapies to treat cancer patients, including patients with
prostatic carcinomas. For instance, Salgaller et al (1998) treated
prostate cancer patients using DC pulsed with prostate membrane
specific antigen (PMSA)-associated peptides. The results of this
and similar clinical trials were quite optimistic. However, presence
of patients with limited or no responses suggests that immunobi-
ology of DC in in vivo tumour microenvironment might be
different from our expectations and indicates the actual need for
the improvement of modern DC-based immunotherapies. We
hypothesized that one of the reasons for the limited efficacy of the
immune responses in treated patients may be the prostate cancer-
induced suppression and elimination of DC.
Premature apoptosis of DC, induced by different tumour cell
lines, has been described early (Esche et al, 1999). However,
signal transduction pathways regulating this phenomenon as well
as mechanisms of DC protection were not yet investigated. It has
been recently demonstrated that cytokines may increase survival
of immune cells, including DC, in cultures and that this effect was
mediated by the up-regulated expression of anti-apoptotic proteins
which belong to the Bcl-2 family of proteins. For example, CD40L
(CD154) has been reported to stimulate DC maturation and
survival in vitro (Bjorck et al, 1997; Mackey et al, 1998).
Interestingly, CD40 ligation on other cell types was associated
with increased expression of anti-apoptotic proteins Bcl-2 and Bcl-
xL (Ning et al, 1996; Alam et al, 1997; Akifusa et al, 1998).
Interleukin 12 (IL-12), a proinflammatory cytokine with a wide
spectrum of functions, enhances the survival of hematopoietic
progenitor cells (Ploemacher et al, 1993; Bellone and Trinchieri,
1994). Interleukin-15 (IL-15), a cytokine with similar to IL-2
activities, was also shown to increase survival of NK cells (Carson
et al, 1997) and lymphocytes (Bulfone-Paus et al, 1997; Lorenz et
al, 1997). These effects of IL-15 were accompanied by up-regula-
tion of expression of anti-apoptotic protein Bcl-2 in lymphocytes
(Carson et al, 1997; Lorenz et al, 1997). Thus, cytokines may regu-
late differentiation and survival of immune cells. However, their
effect on immune cell survival in the tumour microenvironment
was not evaluated.
The aims of this study were to (i) determine whether human
prostate cancer may cause apoptosis of human DC, (ii) evaluate
possible mechanisms of DC death and (iii) examine the role of
cytokines IL-12 and IL-15 in the protection of DC from tumour-
induced cell death. Using several different approaches, we have
demonstrated that three different prostate cancer cell lines caused
apoptotic death of DC during co-incubation. CD40 ligation on DC
induced production of IL-12 and IL-15, which both increased
resistance of DC to prostate cancer-induced apoptosis by up-regu-
lating expression of Bcl-2 proteins.
MATERIALS AND METHODS
Cells
Prostate cancer cell lines, LNCaP, DU-145 and PC-3, were
cultured in RPMI 1640 medium (GIBCO, Grand Island, NY)
supplemented with 2 mM L-glutamine, 100 units/ml penicillin,
100 mg/ml streptomycin, 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids, and 5% heat inactivated fetal bovine
serum (FBS) (all from GIBCO). Human normal prostate epithelial
cells (PrEC) were obtained from Clonetics Corporation
(Walkersville, MD) and maintained in special medium according
to the manufacturer’s recommendations.
Dendritic cells were generated from CD14+ monocytes
obtained from human peripheral blood of healthy volunteers. After
gradient separation on HistoPrep medium (1.077 g/ml; Sigma, St.
Louis, MO), adherent cells were isolated from peripheral blood
mononuclear cells (PBMC) on plastic (37°C, 2 hours) and cultured
in tissue flasks in complete medium, consisting of AIM-V
(GIBCO), 2.5% heat inactivated human AB serum (Sigma), 1
mg/ml indomethacin (Sigma) and 50 mM N-methyl-L-arginine
(Alexis, San Diego, CA). 1000 U/ml rhGM-CSF and 1000 U/ml
rhIL-4 (a gift from Schering-Plough Research Institute,
Kenilworth, NJ) were added to the cultures every 3 days. Non-
adherent cultured DC were harvested 7–10 days later and DC
phenotype was confirmed by flow cytometry. Cultured cells were
CD14-, CD3-, CD20-, HLA-DR+, CD80+, CD86+, CD40+
suggesting a common phenotype of cultured monocyte-derived
DC.
Experimental design
Cultured DC were collected, purified from dead cells (usually
<5–10%), counted and incubated with human prostate cancer cell
lines LNCaP, DU-145 or PC-3 in 6-well plates. Cells were sepa-
rated using membrane inserts with 0.4 mm pore size. Five to 10 ´
105 DC were placed in wells with 2 ml complete medium. One to 2
´ 106 prostate cancer cells resuspended in 2 ml of medium were
placed in the inserts. As controls, DC were co-incubated with
normal human prostate epithelial cells PrEC, human PBMC or
tumour medium alone. DC were collected 24 and 48 hours later
and apoptosis was assessed by the morphological criteria, TUNEL
staining and Annexin V binding assay.
To evaluate whether cytokines protect DC from tumour-induced
apoptosis, cultured DC were stimulated with IL-12, IL-15 and
CD40 ligand (CD154) for 24 hours before the co-incubation with
LNCaP prostate cancer cells. One hundred ng/ml of recombinant
human IL-12 (rhIL-12, a gift from Hoffman-La Roche Inc.,
Nutley, NJ), and 300 ng/ml of recombinant human IL-15 (rhIL-15,
Immunex Corp., Seattle, WA) were used in these studies. Two
methods were used for the stimulation of CD40 on the surface of
DC. In one case, L-cells (murine fibroblasts) transfected with
human CD40 ligand (CD40L/L-cells) (Arpin et al, 1995) were
used to activate DC. DC were incubated with adherent CD40L/L-
cells for 24 hours prior to their co-incubation with prostate cancer
cells. DC incubated with nontransfected L-cells served as controls.
In the second case, mouse anti-human CD40 antibodies (1 mg/ml,
Upstate Biotechnology, Lake Placid, NJ) were used to stimulate
DC in cultures for 24 hours followed by the co-incubation with
tumour cells. DC stimulated with mouse IgG (Sigma) at the same
concentration provided a control for these experiments.
Assessment of apoptosis
Morphologic evaluation
Dendritic cells were harvested after co-incubation with tumour
cells and placed on microscope slides using a standard Cytospin
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Cells were stained with a LeukoStat Stain Kit (Fisher Scientific,
Pittsburgh, PA) and the percentage of apoptotic cells was assessed
quantitatively using morphologic criteria, including condensation
of chromatin, reduction in nuclear size, shrinkage of total cell
volume, increased cell density, and a formation of apoptotic bodies
(Kerr et al, 1972).
Annexin V assay
DC were collected and double-stained with FITC-conjugated
Annexin V (PharMingen, San Diego, CA) and propidium iodide
(PI) (Sigma). Annexin V was added according to the manufac-
turer’s recommendations. PI was used at a final concentration of
10 mg/ml. The percentage of cells undergoing apoptosis in a quan-
titative manner was determined as percentage of Annexin V posi-
tive PI negative cells. Samples were analysed by the FACScan
flow cytometer with LYSYS II software package (Becton
Dickinson, San Jose, CA).
TUNEL staining
Cells were collected, washed, counted, and 106 cells/ml were fixed
consecutively in 4% formaldehyde and 80% ethanol. Fixed cells
were placed on glass slides using Cytospin centrifuge. TdT-FragEl
DNA fragmentation detection kit (Oncogene Research Products,
Cambridge, MA) was used for terminal deoxynucleotidyl trans-
ferase and nick translation (TUNEL) assay to determine the apop-
tosis. TUNEL positive and negative cells were counted at least in
ten different fields and the number of apoptotic cells was
expressed as the percentage of TUNEL positive cells.
RT–PCR
Total RNA from harvested DC was extracted by Quanidium
method with RNAZol B (Biotek Lab. Inc., Houston, TX)
following the procedure recommended by the manufacturer.
Briefly, homogenized samples were mixed with RNAZol B, incu-
bated on ice for 5 min and mixed with 1/10 volume of chloro-
form. Then samples were vigorously shaken for 15 sec, incubated
on ice for 5 min and centrifuged at 12 000 g for 15 min at 4°C.
Aqueous phase was transferred into an equal volume of
isopropanol and incubated at –20°C for at least 15 min. RNA was
then precipitated by centrifugation and washed with ethanol. The
dried pellet was dissolved in diethylpyrocarbonate (DEPC)-
treated water and the amount of RNA was determined by a spec-
trophotometric reading at 260 nm. Synthesis of DNA was carried
out in a 50 mM Tris-HCl buffer (pH 8.3) containing 75 mM KCl,
3 mM MgCl2, 10 mM DTT, 40 U/ml RNAse inhibitor, 200 U/ml
Molony Murine Leukemia Virus (MMLV)-Reverse Transcriptase,
1.25 mM of each dATP, dTTP, dGTP, dCTP, 20 mg/ml oligo-dT
and isolated RNA samples, which were preheated at 70°C and
cooled on ice. The reaction mixture was incubated at 37°C for one
hour followed by a brief heat inactivation of the enzyme. The
synthesized cDNA was subjected to PCR amplification with
human  b-actin primers to verify the quality of RNA/cDNA prepa-
ration: 5¢-GCATCGTCACCAACTGGGACGAC-3¢ and 5¢-
ATTTGCGGTGGACGATGGAGGGGC-3¢. All samples tested
for the hIL-12 mRNA expression were confirmed to be b-actin
positive. To verify that the PCR product was not amplified from
residual DNA left in RNA samples, RNA preparations from all
samples without cDNA step (RT negative control) were subjected
to b-actin PCR amplification. The following primers for hIL-12
p40 were used: 5¢-ATTGAGGTCATGGTGGATGC-3¢ and 5¢-
AATGCTGGCATTTTTGCGGC-3¢. To perform a PCR, synthe-
sized cDNA (100 ng or more RNA equivalent cDNA) was added
to a final volume of 100 ml 10 mM Tris-HCl buffer (pH 8.3)
containing 50 mM KCl, 1.5 mM MgCl2, 200 mM dNTP, 0.2 mM
primer and 2.5 U/ml Taq DNA polymerase (Perkin Elmer,
Norwalk, CT). The reaction was performed in a thermal cycler
(Perkin Elmer) at 94°C 1 min, 60°C (for b-actin) or 55°C (for
hIL-12 p40) 1 minute, and 72°C 1 minute each cycle, for the total
of 30 to 35 cycles, with an extension of 10 minutes at 72°C after
the last cycle. To detect the PCR product, 40 ml of PCR samples
were loaded on an agarose gel at the appropriate concentration
followed by electrophoresis.
Human IL-15 was detected by RT–PCR using primers: 5¢-
AGCCAACTGGGTGAATGTAA-3¢ and 5¢-TTGCATCCAGAT-
TCTGTTAC-3¢ with similar conditions as described above for the
hIL-12-related procedures.
The comparison and analysis of mRNA expression was done by
volume quantitation using BioRad Densitometer. Sample/b-actin
ratio was first calculated for each sample and then used for
comparison. Thus, increased expression of mRNA is presented as
a percentage from the control (non-stimulated) value.
Western blot
The expression of anti-apoptotic protein Bcl-xL in DC was
assessed using Western blot technique. Cells were collected,
washed in PBS and homogenized in a lysing buffer. The
homogenate was then centrifuged at 12 000 g for 15 min at 4°C.
The protein concentration in the supernatant was determined by
the Bradford method, using BioRad protein kit (Bio-Rad
Laboratories, Hercules, CA). Each sample was denaturated for 5
min at 100°C in a sample buffer. Equal amounts of protein were
loaded for each sample and electrophoretically separated on
16.5% SDS-PAGE followed by transfer to a nitrocellulose
membrane. The membrane was blocked with 0.2% nonfat milk
(BioRad) and 0.1% Tween-20 (Fisher) in 20 mM Tris-saline
buffer at pH 7.2. Bcl-xL protein was detected using specific rabbit
primary antibodies (Oncogene Research Products) with the final
concentration of 2.5 mg/ml, and donkey anti-rabbit secondary
antibodies (1: 5000 dilution, Amersham Pharmacia Biotech Inc.,
Piscataway, NJ). The membrane was processed and treated with
chemiluminescence reagents (Tropix, Medford, MA). The bands
were visualized on a Kodak film exposed to the membrane to
detect chemiluminescence signals. The comparison and analysis
of protein expression was performed using BoiRad Densitometer
as described above.
Statistical analysis
Chi-square analysis was performed to evaluate the significance of
differences between the experimental groups in the Annexin V
staining assays, when discrete data were presented. For a single
comparison of two groups, the Student’s t-test (SigmaStat
Statistical Software, SPSS, Chicago, IL) was used. If data distrib-
ution was not normal, Mann-Whitney rank sum test was
employed. For all analysis, the level of significance was set at a
probability of 0.05 to be considered significant. Data are
presented as the mean ± SEM.
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Co-incubation of prostate cancer cells and DC resulted
in apoptotic death of DC
DC were co-incubated with LNCaP, DU-145 and PC-3 cells across
the membrane with 0.4 mm pore size, collected, and the levels of
apoptosis were determined after 24 and 48 hours. DC co-incubated
with PrEC, PBMC and tumour medium served as controls. The
evaluation of DC survival incubated with prostate cancer cells or
control cells demonstrated a marked difference in resulted cell
morphology, including condensed cytoplasm and nuclei, degrada-
tion of chromogen and formation of apoptotic bodies in DC
cultures co-incubated with tumour cells (Figure 1). According to
the morphologic evaluation, DC incubated with LNCaP, DU-145,
PC-3, PBMC and tumour medium had an apoptotic rate of 23.65 ±
2.90%, 27.77 ± 4.61%, 22.32 ± 2.51%, 7.41 ± 1.30% and 7.25 ±
1.03%, respectively (Figure 2). Statistical analysis of data
confirmed significantly lower numbers of apoptotic cells in DC
cultures co-incubated with PrEC or PBMC in comparison with DC
cultures co-incubated with LNCaP (P < 0.001), DU-145 (P < 0.01)
and PC-3 (P < 0.001) tumour cell lines. Furthermore, neither
proliferation of tumour cells nor depletion of nutrients within the
culture medium was responsible for the DC apoptosis as was
shown in additional experiments with multiple replacement of
tumour cells. We next confirmed these results using Annexin V
binding assay: levels of DC apoptosis were 30.89 ± 4.10%, 18.95
± 10.81%, 24.62 ± 4.70%, 8.26 ± 1.78% and 5.27 ± 1.90% in DC
cultures co-incubated with LNCaP, DU-145, PC-3 PBMC and
medium, respectively. Prostate cancer cell-induced suppression of
DC survival in cultures was statistically significant as compared to
control value (P < 0.001 in all cases) (Figures 2 and 3). Analysis of
TUNEL staining in different DC cultures confirmed that pre-incu-
bation of DC with prostate cancer cells resulted in a significant
increase in TUNEL-positive cell numbers in these cultures (Figure
1). Each experiment was repeated at least twice. Taken together,
these data demonstrated that prostate cancer cells significantly
shortened the life-span of DC in cultures by increasing the levels
of apoptotic death in these cells.
CD40 ligation protected DC from prostate cancer-
induced apoptosis
Since it has been shown early that CD154 might prolong DC
survival in cultures, we have examined the influence of CD40 liga-
tion on DC survival in the prostate cancer microenvironment in
vitro. Incubation of human DC with CD154 (CD40L)-transfected
L-cells for 24 hours before the co-incubation with LNCaP cells,
decreased the morphological appearance of apoptosis from 18.39
± 1.63% in DC cultures pre-incubated with non-transfected L-cells
to 9.55 ± 1.60% (P < 0.01). Analysis of an Annexin V binding
assay revealed the similar data and confirmed the significant
decrease of prostate cancer-induced apoptotic rate by 16% (P <
0.01) in cultured DC after CD40 ligation.
The alternative way of stimulation of CD40 receptor using anti-
CD40 antibodies confirmed our results. For instance, activation of
DC with anti-CD40 antibodies for 24 hours followed by the co-
incubation with LNCaP prostate cancer cells resulted in 13.49 ±
2.80% of apoptosis in DC, whereas pre-incubation of DC with
isotype-matched control IgG followed by the co-incubation with
LNCaP cells caused apoptosis in 21.89 ± 5.51% of DC, as was
assessed by Annexin V binding assay (P < 0.001). All experiments
were repeated at least twice with the same effect. Thus, our data
demonstrated that ligation of CD40 receptors on DC led to DC
activation and increased their resistance to prostate cancer-induced
apoptosis.
Cytokines IL-12 and IL-15 protected DC from prostate
cancer-induced apoptosis
To determine the resistance of cytokine-activated DC to the
induction of cell death in the tumour microenvironment, we have
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Figure 1 Prostate cancer cells cause apoptosis of human dendritic cells.
Incubation of human cultured DC with LNCaP cells (B) caused morphological
alterations of DC which correspond to the features of apoptotic cell death.
Incubation of DC with PBMC, instead of tumour cells, served as a control (A).
DC were harvested after 48 hours of co-incubation, fixed, stained with Eosin
Y and Methylene blue and analysed by light microscopy (´ 400), as
described in Materials and Methods. TUNEL staining of DC confirmed that
co-incubation of DC with LNCaP cells resulted in a significant increase in the
levels of DC apoptosis, as can be seen as brown (TUNEL+) cells in insets
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Figure 2 Three different prostate cancer cell lines cause apoptosis of
human dendritic cells. The levels of apoptotic death in DC cultures were
significantly increased after 48 hours of co-incubation with different prostate
cancer cells when compared with control DC cultures co-incubated with
PrEC, PBMC or tumour medium. DC were generated from human adherent
PBMC, co-incubated with tumour or control cells, harvested, washed and
analysed. The percentage of apoptotic cells was determined by the
morphological features and Annexin V binding assay, as described in
Materials and Methods.*P < 0.01 compare to the control groupexamined whether cytokines IL-12 or IL-15 protect DC from
prostate cancer-induced apoptosis. Cultured DC were stimulated
with rhIL-12 (100 ng/ml) or rhIL-15 (300 ng/ml) for 24 hours
before the co-incubation with LNCaP cells. Cell viability was
assessed by the morphologic examination, TUNEL staining and
Annexin V binding assay.
Morphologic evaluation of DC survival demonstrated that
levels of DC apoptosis in cultures co-incubated with PBMC
(control), LNCaP alone or LNCaP following IL-12 or IL-15 stim-
ulation were 5.51 ± 2.12%, 16.58 ± 2.01%, 9.06 ± 2.70%, and 5.80
± 2.75%, respectively. These data showed that cytokines IL-12 and
IL-15 significantly decreased the level of tumour-induced apop-
tosis in DC (P < 0.05 for IL-12 and P < 0.01 for IL-15) (Figure 4).
Similarly, TUNEL staining demonstrated the tumour-induced
apoptotic rate of 6.59 ± 0.48%, 15.12 ± 1.86%, 5.50 ± 0.77%, and
6.92 ± 1.14% in the same DC cultures, respectively (P < 0.001 for
IL-12 and P < 0.01 for IL-15). Annexin V binding assays further
confirmed these data: DC apoptotic rates were 11.02 ± 0.90%,
27.26  ± 4.26%, 18.97 ± 2.95%, and 17.73 ± 9.18% in DC +
PBMC, DC + LNCaP, DC/IL-12 + LNCaP, and DC/IL-15 +
LNCaP cultures, respectively. Cytokine-mediated protection of
DC from prostate cancer-induced apoptotic death was statistically
significant (P < 0.001 for both IL-12 and IL-15). Thus, altogether
these results suggested that IL-12 and IL-15 protect DC from
prostate cancer-induced cell death in vitro.
CD154 induced increased expression of IL-12 and IL-15
by DC
Since it has been reported that DC produce IL-12 and IL-15 upon
stimulation, we have evaluated the possible mechanism of the
protective effect of CD154 on DC survival in the prostate cancer
microenvironment and examined whether CD154 might increase
the expression of IL-12 and IL-15 in cultured DC. CD154 is a
known promoter of IL-12 expression on various cells, including
DC (Cella et al, 1996; Kelsall et al, 1996). However, its effect on
IL-15 expression was not studied yet. Human DC were incubated
with human CD154-transfected L-cells. DC were harvested after
24 hours and RT–PCR was performed to evaluate IL-12 and IL-15
mRNA expression. DC incubated with non-transfected L-cells for
24 hours served as controls. We found that CD154-transfected L-
cells induced a marked increase in expression of both IL-12 and
IL-15 mRNA as compared to controls (Figure 5). For instance,
expression of IL-12 p40 in DC co-incubated with non-transfected
L-cells (control) was 0.59 (ratio between the densitometry units of
the sample band and the corresponded b-actin band), whereas the
p40 expression in DC co-incubated with CD154-transfected L-
cells was 1.58 (Figure 5A). These results demonstrated that CD40
ligation on cultured human DC increased IL-12 expression up to
270%. Next, IL-15 mRNA expression increased from 0.29 in
control DC to 1.02 in DC activated by CD154 (Figure 5B),
suggesting that CD40 ligation resulted in stimulation of IL-15
expression up to 350%. Taken together, these data showed that
CD40L-mediated activation of DC caused a marked stimulation of
IL-12 and IL-15 mRNA expression, which may lead to the
increased survival of DC.
CD154 induced increased expression of the anti-
apoptotic protein Bcl-xL
Since it has been shown that CD154-mediated stimulation of B
cell was accompanied by an increased expression of anti-apoptotic
protein Bcl-xL, we hypothesized that similar mechanisms might be
involved in CD154-induced protection of human monocyte-
derived DC survival in the prostate cancer microenvironment. To
test this hypothesis, we examined Bcl-xL expression in DC
following the stimulation with CD154. Cultured DC were co-incu-
bated with CD154-transfected and control L-cells for 24 hours,
harvested and Western blot analysis was performed to detect 
Bcl-xL protein expression. We found a marked increase in 
the expression of Bcl-xL by DC after the co-incubation with
CD154-transfected L-cells, as compared to controls (Figure 6A).
For instance, expression of Bcl-xL in CD154-activated DC reached
1182.44 units compared to 506.89 units in DC co-incubated with
non-transfected control L-cells. However, co-incubation of DC
with control L-cells caused activation of Bcl-xL expression by
itself in comparison to intact DC (up to 3-fold). This effect is due
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Figure 3 FACScan detection of apoptotic changes in the membranes of
human dendritic cells after co-incubation with LNCaP cells. Cultured human
DC were co-incubated with LNCaP cells (A) or control PBMC (B) separated
by a membrane with 0.4 mm pore size for 48 hours. DC were harvested,
washed, and the level of apoptotic death was determined using Annexin V (x
axis) and propidium-iodide (PI) (y axis) binding assay as described in
Materials and Methods. Annexin-positive (apoptotic) and PI negative (non-
necrotic) cells are localized in the right lower quadrant
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Figure 4 Activation of dendritic cells with cytokines increases their
resistance to tumour-induced apoptosis. Cultured human DC were treated
with cytokines IL-12 and IL-15 for 24 hours before the co-incubation with
prostate cancer cells. DC were then collected, washed and the levels of
apoptosis were assessed by the morphologic evaluation, TUNEL staining
and an Annexin V binding assay, as described in Materials and Methods.
Pretreatment of DC with cytokines significantly decreased levels of prostate
cancer-induced apoptosis of DC.*P < 0.01 and #P < 0.05 compared to the
control groupto a non-specific activation of human DC by murine L-cells. Thus,
stimulation of Bcl-xL expression in DC may be one of the mecha-
nisms responsible for increased survival of CD40L-activated DC
in the prostate cancer microenvironment.
IL-12 and IL-15 increased expression of the anti-
apoptotic protein Bcl-xL by DC
Next, we examined whether cytokine-induced protection of DC
from prostate cancer-induced apoptosis might be mediated by an
increased expression of anti-apoptotic proteins. Cultured DC were
incubated with either hrIL-12 (100 ng/ml) or hrIL-15 (300 ng/ml)
for 24 hours and the expression of Bcl-xL was determined by a
Western blot. The result demonstrated that stimulation of DC with
IL-12 or IL-15 in vitro resulted in increased expression of anti-
apoptotic protein Bcl-xL (Figure 6B). For example, expression of
Bcl-xL in control DC corresponded to 163.41 units and was
increased to 344.51 units by IL-12 and to 537.17 units by IL-15.
Thus, these data suggest that cytokine-induced expression of Bcl-
xL in DC might explain the elevated resistance of DC to prostate
cancer-induced apoptosis after stimulation with IL-12, IL-15 or
CD40L.
DISCUSSION
Initiation of a specific antitumour immune response requires
presentation of tumour-associated antigen(s) (TAA) to T cells by
APC. In fact, it has been well documented that DC, the most potent
APC, are capable of recognising, processing and presenting TAA,
in turn initiating a specific antitumour immune response (Shurin,
1996). It is also known that infiltration of various tumours with DC
confers them favourable prognosis (Becker, 1992; Lotze, 1997).
Therefore, it is possible to hypothesize that dysfunction of the DC
system may lead to a failure of antitumour immune responses.
Prostate cancer was found to be sparse in tumour-infiltrating DC in
comparison with benign prostate hyperplasia and normal prostate
tissues. The number of DC further decreased in the high-grade
prostate carcinomas (Bigotti et al, 1991; Davidson et al, 1997;
Troy et al, 1998), which carry the worst prognosis (Eastham and
Scardino, 1998). It is possible that active suppression of the host
immune system, together with loss or attenuation of class I expres-
sion by prostate cancer (Bander et al, 1997) may be responsible for
the depressed immunity in prostate cancer patients (Ivshina et al,
1995; Healy et al, 1998; Salgaller et al, 1998). Understanding of
prostate cancer immunobiology and, in particular, the immunobi-
ology of DC, will help in the development of effective
immunotherapy for this disease.
Decreased number of infiltrating DC in prostate cancer tissue
allowed us to speculate on the possibility of active elimination of
DC by prostate cancer-derived factors within the tumour microen-
vironment. In fact, all three prostate cancer cell lines tested in this
study, LNCaP, DU-145, and PC-3, demonstrated a significant
effect on DC survival, as was assessed by the morphological
features, TUNEL staining and Annexin V binding assay. This
suggests that prostate cancer might actively eliminate DC from the
tumour tissue. Although the observed apoptotic rate of DC seems
to be not very high, in the real tumour environment tumour-to-DC
ratio is probably several times higher than the one used in our
experiments, and apoptotic signals may act for a longer period of
time, resulting in complete elimination of DC from prostate cancer
tissues. The absence of DC in human prostate cancer tissues,
described by Troy et al (1998), may be explained by a high level of
prostate cancer-induced DC apoptosis in vivo. However, it is
unknown which prostate cancer-derived factors may be involved
in this phenomenon. A variety of tumours, including prostate
cancer (Stearns and Wang, 1998; Sharma et al, 1999; Stearns et al,
1999; Wang et al, 1999), have been shown to release IL-10, a
cytokine that could enhance the spontaneous apoptosis in DC
(Ludewig et al, 1995). TGF-b is another candidate cytokine, which
has been shown to be released by prostate cancer cells (Burchardt
et al, 1999; Wikstrom et al, 1999; Cardillo et al, 2000) and might
affect DC as well (Caux et al, 1999; Strobl and Knapp, 1999). It is
also possible that prostate cancer cells produce NO (Klotz et al,
1998), which in turn could cause apoptosis in DC. Taken together,
these data suggest that prostate cancer-derived factors might cause
apoptotic death of DC in the tumour microenvironment. Together
with our data, these results provide a new mechanism demon-
strating how prostate cancer escapes from immune recognition and
raise the next question about the possible mechanisms of DC
protection from prostate cancer-induced cell death.
It has been recently reported that CD154 binds to CD40 on DC,
leading to their increased survival in cultures (Bjorck et al, 1997;
Mackey et al, 1998). This fact allowed us to hypothesize that
CD40 ligation on DC may also protect them from prostate cancer-
induced apoptosis. To test this hypothesis, we used two methods to
stimulate CD40 on DC: (i) adherent L-cells transfected with
human CD154 and (ii) specific anti-CD40 antibodies. In both
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Figure 5 CD40 ligation on human dendritic cells results in increased
expression of IL-12 and IL-15 mRNA. Cultured human PBMC-derived DC
were stimulated with CD40L (CD154)-transfected or control (non-transfected)
L cells for 24 hours, harvested and washed. The expression of IL-12 mRNA
(A) and IL-15 mRNA (B) was determined as described in Materials and
Methods. Analysis of RT–PCR products suggested that CD40 ligation on
human DC markedly increased the expression of IL-12 and IL-15 mRNA.
Lanes for A: 1, DC + L-cells (control); 2, DC + CD154/L-cells; 3, negative
control; 4, positive control; 5 and 6, b-actin for 1 and 2, respectively; 7,
molecular weight markers. Lanes for B: 1, molecular weight markers; 2, DC +
L-cells (control); 3, DC + CD154/L-cells
Figure 6 Activation of human DC with IL-12, IL-15 or CD40L results in
increased expression of anti-apoptotic protein Bcl-xL. Cultured human PBMC-
derived DC were stimulated with CD40L (CD154)-transfected or control (non-
transfected) L-cells (A), IL-12 (100 ng/ml) or IL-15 (300 ng/ml) (B) for 24
hours, harvested and washed. The expression of Bcl-xL by DC was
determined by Western blot as described in Materials and Methods
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Bcl-XLcases, increased resistance of CD40L-activated DC to prostate
cancer-induced death was demonstrated. Since we have shown
early that LNCaP cells express Fas ligand (CD95L) (Salup et al,
1998) and DC express Fas (Shurin et al, 1999), it is possible that
induction of apoptosis in DC by prostate cancer is due to
CD95/CD95L interaction. This mechanism remains to be evalu-
ated. Furthermore, CD40 stimulation of DC was shown to coun-
teract CD95/CD95L mediated DC apoptosis in cultures (Bjorck et
al, 1997). It is likely that increased expression of anti-apoptotic
proteins Bcl-2 (Bjorck et al, 1997) and Bcl-xL (Figure 6) is
involved in DC protection from tumour-induced cell death. Bcl-xL
was effective at rendering B cells resistant to CD95/CD95L-medi-
ated killing (Schneider et al, 1997), and it may have played the
same role in our experiments. Further studies are in progress to
verify this hypothesis. Interestingly, CD40 stimulation does not
lead to increased expression of Bcl-xL in other types of cells (Sbih-
Lammali et al, 1999) suggesting a cell-specific mechanism.
CD154 is a known inducer of IL-12 production (Cella et al,
1996; Kelsall et al, 1996; Nakajima et al, 1998). CD154 is being
expressed on T lymphocytes, and CD154/CD40 interaction is
extremely important for DC and T cell communication and mutual
support. The stimulation of CD40 receptor on DC leads to the
increased production of IL-12, which in turn stimulates the expres-
sion of CD154 on T cells (Peng et al, 1998), reverse anergy of
CD+ 4T cells (Grohmann et al, 1998), and stimulates interferon-g
production by T and NK cells (Kobayashi et al, 1989; Chan et al,
1991; Kubin et al, 1994). As shown in this study, CD40 stimula-
tion also leads to the increased expression of IL-15. IL-15 may
serve as an attractant for the T cells during the DC/T cell interac-
tion (Jonuleit et al, 1997). IL-15 also induces T cell proliferation
and promotes IL-12 production (Avice et al, 1998). Together with
IL-12, IL-15 has been shown to stimulate NK cells to produce
interferon-g, tumour necrosis factor-a and macrophage inhibitory
factor-1a (Carson et al, 1995; Bluman et al, 1996). Since both IL-
12 and IL-15 are involved in the DC/T cells interaction, promote T
cell activity (Heufler et al, 1996; Jonuleit et al, 1997), and increase
survival of DC, CD154 stimulation of DC should lead to an
increased immunologic response. In fact, using a murine tumour
model, we have recently demonstrated that the stable transfection
of colon adenocarcinoma cells with CD154 gene resulted in a
significant inhibition of tumour growth in vivo, which was accom-
panied by an increased infiltration of tumour tissues with DC and
T cells (Esche et al, 1999).
Thus, IL-12 and IL-15 protected DC from prostate cancer-
induced apoptosis. This effect, at least in part, was mediated by the
increased expression of the anti-apoptotic protein Bcl-xL in DC.
We believe that CD40 stimulation of DC induces increased expres-
sion of Bcl-xL both directly and indirectly via IL-12 and IL-15
release. Thus, it is likely that IL-12 and IL-15 might regulate DC
survival by an autocrine mechanism. These DC regulatory proper-
ties of CD154, IL-12 and IL-15 may play an important role during
the induction and development of the immune responses to
prostate cancer by increasing resistance of DC to prostate cancer-
induced cell death. Further work is needed to reveal the mecha-
nism of prostate cancer-induced apoptosis of DC and to develop
the most effective methods of DC protection.
In summary, our data demonstrated for the first time that human
prostate cancer cells LNCaP, DU-145, and PC-3 cause apoptosis 
of human DC in vitro. This apoptosis-inducing effect could 
be partly blocked by the stimulation of DC by CD154, IL-12 or 
IL-15. Anti-apoptotic protein Bcl-xL is involved in the protection
of DC from prostate cancer-induced apoptosis. Taken together,
these findings might serve as a basis for the development of new
experimental approaches designed to increase efficacy of DC-
based immunotherapies of cancer.
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